KRRO 110pla
Alternative Names: KRRO-110Latest Information Update: 24 May 2024
At a glance
- Originator Korro Bio
- Class Oligonucleotides
- Mechanism of Action Alpha 1-antitrypsin modulators; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alpha 1-antitrypsin deficiency
Most Recent Events
- 20 May 2024 Updated pharmacodynamics data from a preclinical trial in Alpha-1 antitrypsin deficiency released by Korro Bio
- 23 Apr 2024 Korro Bio plans a phase I/II trial for Alpha-1 antitrypsin deficiency
- 18 Apr 2024 Korro Bio announced the intention to submit regulatory filing for First-in-Human (FIH) study of KRRO 110 in Alpha-1 antitrypsin deficiency (AATD) patients in the second half of 2024